People suffering from migraines will soon have access to pain relief in the form of a nasal spray.

The U.S. Food and Drug Administration (FDA) has approved the first calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray intended to treat migraines in adults. 

Pfizer produces the medication, called Zavzpret. It works by blocking CGRPs, a protein that is released around the brain and triggers migraines.

News of the FDA’s approval came after two randomized, double-blind, placebo-controlled studies, Pfizer noted in a press release announcing the approval.

MIGRAINE VS. HEADACHE: HOW TO TELL THE DIFFERENCE AND WHEN TO SEEK HELP

“The FDA approval of Zavzpret marks a significant breakthrough for people with migraine who need freedom from pain and prefer alternative options to oral medications,” said Angela Hwang, president of Pifizer’s global biopharmaceuticals business in New York City, in the press release. 

Should the government force everyone to get vaccinated?

By completing the poll, you agree to receive emails from Being Healthy News, occasional offers from our partners and that you've read and agree to our privacy policy and legal statement.

“Zavzpret underscores Pfizer’s commitment to delivering an additional treatment option to help people with migraine gain relief and get back to their daily lives.”

Pfizer touts quick pain relief as the biggest benefit of Zavzpret. 

Continue Reading >>

H/T Fox News (read more at FoxNews.com)

The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of Being Healthy News. Contact us for guidelines on submitting your own commentary.